SPYRE THERAPEUTICS, INC. (SYRE) Operating cash flow 2016–2025
SPYRE THERAPEUTICS, INC. (SYRE) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$169.3MFY2025 · since FY2016: -$18.8M → -$169.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$169.3M | -7.5% |
| FY2024 | -$157.4M | -57.6% |
| FY2023 | -$99.9M | -24.7% |
| FY2022 | -$80.1M | -49.2% |
| FY2021 | -$53.7M | +29.1% |
| FY2020 | -$75.8M | -15.3% |
| FY2019 | -$65.7M | -104.1% |
| FY2018 | -$32.2M | -30.8% |
| FY2017 | -$24.6M | -30.7% |
| FY2016 | -$18.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SYRE financial trends
SYRE RevenueSYRE Net incomeSYRE Net marginSYRE Gross profitSYRE Gross marginSYRE Operating incomeSYRE Operating marginSYRE Free cash flowSYRE Capital expendituresSYRE Return on equitySYRE Stock buybacksSYRE Dividends paidSYRE Total assetsSYRE Total liabilitiesSYRE Shareholders’ equitySYRE overview →